Cargando…
cIAP1/2 inhibition synergizes with TNF inhibition in autoimmunity by down-regulating IL-17A and inducing T(regs)
IL-17 and TNF-α are major effector cytokines in chronic inflammation. TNF-α inhibitors have revolutionized the treatment of rheumatoid arthritis (RA), although not all patients respond, and most relapse after treatment withdrawal. This may be due to a paradoxical exacerbation of T(H)17 responses by...
Autores principales: | Kawalkowska, Joanna Z., Ogbechi, Joy, Venables, Patrick J., Williams, Richard O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494502/ https://www.ncbi.nlm.nih.gov/pubmed/31049403 http://dx.doi.org/10.1126/sciadv.aaw5422 |
Ejemplares similares
-
Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016) -
Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2
por: Darding, M, et al.
Publicado: (2011) -
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC
por: Yang, Chengcheng, et al.
Publicado: (2016) -
Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
por: Mitsuuchi, Y, et al.
Publicado: (2017) -
Cytoplasmic and Nuclear Functions of cIAP1
por: Zadoroznyj, Aymeric, et al.
Publicado: (2022)